New drugs and targeted therapeutic agents in ovarian cancer;Nouvelles molécules et thérapeutiques moléculaires ciblées dans les adénocarcinomes ovariens de stades avancés

Bulletin du Cancer

Volumn 96, Issue 12, 2009, Pages 1215-1224

  De La Motte Rouge, T ^a   Petrella, M C ^a   Michels, J ^a   Even, C ^a   Balleyguier, C ^a   Duclos, J ^a   Mazeron, R ^a   Morice, P ^a   Pautier, P ^a   Lhomme C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bevacizumab; Chemotherapy; Olaparib; Ovarian cancer; Targeted therapies

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BIBF 1120; CANFOSFAMIDE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; TRASTUZUMAB; UNINDEXED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG SAFETY; HUMAN; MOLECULAR THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; FEMALE; IMMUNOTHERAPY; OVARY TUMOR; PHASE 3 CLINICAL TRIAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS;

EID: 74049112703     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.098     Document Type: Review

References (52)

1. Massard C, Lhommé C, Pautier P. Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer. Bull Cancer 2007 ; 94 : 398-404.
2. Boudou-Rouquette P, Pautier P, Morice P, Lhomme C. Prognostic and predictive factors in epithelial ovarian cancer. Bull Cancer 2009 ; 96 : 425-37.
3. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005 ; 23 : 1867-74.
4. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007 ; 97 : 1618-24.
5. Del Campo J, Roszak A, Ciuleanu T, Bidzinski M, Hogberg T, Wojtukienicz M, et al. Phase II open label randomized study of trabectedin (T) given as two differents dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 2006 ; 24 : (suppl; abstr 5031).
6. Monk BJ, Herzog T, Kaye SB, Krasner CN, Vermorken JB, Muggia F, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vs PLD in relapsed, recurrent ovarian cancer (OVA-301). Ann Oncol 2008 ; 19 : (suppl; abstr LBA4).
7. Vergote I, Finkler N, Del Campo J, Lohr A, Hunter J, Matei D, et al. Phase 3 randomised study of canfosfamide (Telcyta[R], TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009.
8. nd line therapy of platinum (P) resistant ovarian cancer (OC). J Clin Oncol 2007 ; 25 : (suppl; abstr LBA5529).
9. Ruegg C, Mutter N. Antiangiogenic therapies in cancer: achievements and open questions. Bull Cancer 2007 ; 94 : 753-62.
10. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 ; 25 : 5165-71.
11. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008 ; 26 : 76-82.
12. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007 ; 25 : 5180-6.
13. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007 ; 105 : 3-6.
14. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007 ; 17 : 771-6.
15. Campos SM, Dizon DS, Cannistra SA, Roche M, Krasner CN, Berlin ST, et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J Clin Oncol 2007 ; 25 : (suppl; abstr 5517).
16. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol 2009; 27: (suppl; abstr 5546).
17. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 ; 354 : 34-43.
18. Konner JA, Grabon D, Pezzulli S, Iasonos A, Sabbatini P, Hensley M, et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 2009 ; 27.
19. McMeekin DD, Lanneau G, Curiel J, Moore K, Walker J, Mannel R. Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. J Clin Oncol 2009 ; 27.
20. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008 ; 26 : 3709-14.
21. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008 ; 110 : 49-55.
22. Tew WP, Colombo N, Ray-Coquard I, Oza AM, del Campo J, Scambia G, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007 ; 25 : (suppl; abstr 5508).
23. Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008 ; 26 : (suppl; abstr 5521).
24. Matulonis UA, Berlin ST, Krasner CN, Tyburski K, Lee J, Roche M, et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2008.
25. Friedlander M, Hancock KC, Benigno B, Rischin D, Messing M, Stringer CA, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J Clin Oncol 2007 ; 25 : (suppl; abstr 5561).
26. Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF-1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009; 27: (suppl; abstr 5501).
27. Biagi JJ, Oza AM, Grimshaw R, Ellard SL, Lee U, Sederias J, et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185. J Clin Oncol 2008 ; 28 : (suppl; abstr 5522).
28. Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008 ; 26 : (suppl; abstr 5537).
29. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003 ; 21 : 283-90.
30. Kaye SB, Poole CJ, Bidzinksi M, Gianni L, Gorbunova V, Novikova E, et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J Clin Oncol 2008 ; 26 : (suppl; abstr 5520).
31. Amler L, Makhija S, Januario T, Matulonis UA, Strauss A, Dizon DS, et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine versus gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol 2008 ; 26 : (suppl; abstr 5552).
32. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006 ; 24 : 4324-32.
33. Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008 ; 98 : 1774-80.
34. Blank SV, Curtin JP, Goldman NA, Runowicz CD, Speyer JL, Tiersten AD, et al. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J Clin Oncol 2006 ; 24 : (suppl; abstr 5076).
35. Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, et al. Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: Final results of a phase II study. J Clin Oncol 2007 ; 25 : (suppl; abstr 5566).
36. Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007 ; 17 : 784-8.
37. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006 ; 101 : 126-31.
38. Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008 ; 113 : 723-32.
39. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008 ; 26 : 3418-25.
40. Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007 ; 110 : 309-17.
41. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007 ; 67 : 2408-13.
42. Armstrong DK, Bicher A, Coleman RL, Gibbon DG, Glenn D, Old L, et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinumsensitive ovarian cancer in first relapse. J Clin Oncol 2008 ; 26 : (suppl; abstr 5500).
43. Fong PC, Boss DS, Carden CP, Roelvink M, De Greve J, Gourley CM, et al. AZD2281 (KU-0059436), a PARP (poly ADPribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol 2008 ; 26 : (suppl; abstr 5510).
44. Audeh MW, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27: [suppl; abstr 5500].
45. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008 ; 26 : 2674-82.
46. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 ; 348 : 203-13.
47. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci (USA) 2007 ; 104 : 3360-5.
48. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008 ; 14 : 3372-9.
49. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, jr., et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004 ; 22 : 3507-16.
50. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009 ; 27 : 418-25.
51. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008 ; 8 : 59-73.
52. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and tnf-alpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008 ; 108 : 421-7.